Back in the game? John Devereux, founder of Genetics Computer Group — now part of Accelrys via Oxford Molecular — has signed on as a consultant with Madison, Wis.-based optical mapping startup OpGen.
Procognia, which acquired Cambridge, UK-based Sense Proteomic in January, will appoint Jonathan Blackburn, formerly Sense’s CSO, to the position of chief scientist.
Shedding his “acting” status after a five-month search process, Edward Rubin has emerged as the new director of DOE’s Joint Genome Institute. Rubin, who has served as interim director since spring 2002, will also take responsibility for directing the genomics division of Lawrence Berkeley National Laboratory.
Consummate genomics jetsetter Audrey Long has found a new home as customer relations and collaborations manager for South San Francisco-based ParAllele following her departure from The Automation Partnership this past winter.
Meanwhile, TAP hired David Phillips as commercial director of the Cambridge, UK-based provider of robotics and automation systems. Phillips most recently served as commercial director of Argenta Discovery.
President George W. Bush announced plans to appoint Eric Lander to the National Cancer Advisory Board, which oversees the NCI and provides peer review for grant applications. Lander would serve on the board for the remainder of a six-year term that expires in March 2006.
Following the discontinuation of Lion’s drug discovery business, CSO Jan Mous has left the company but will serve as consultant. Lion tapped Reiner Doelle for the newly created position of VP for global software development.
The layoffs continue at Lynx. After letting 44 employees go last April, the embattled company laid off 25 percent of its workforce this past January, bringing its total headcount to 90.
Myriad Genetics hired Jerry Lanchbury as senior vice president of research and development, overseeing all non-pharmaceutical R&D at the company.
Richard Love has joined the Translational Genomics Research Institute of Tucson, Ariz., as chief operating officer. Formerly known as the Arizona Bioscience and Biomedicine Institute, TGRI is the result of a joint genomics-to-medicine effort with Arizona State University, the University of Arizona, Northern Arizona University, and the state.
Celera’s Patterson Departs, Returns to Southland
Long the envy of the proteomics field for his access to Celera’s deep pockets, Scott Patterson has left his position as vice president for proteomics at Celera to move back to southern California, the home of Amgen, his previous employer. But Patterson isn’t going so far as to return to his old job. Instead, he started in late January as chief scientific officer of Farmal Biomedicines, a Pasadena-based startup trying to discover new protein therapeutics.
Although Patterson isn’t the only high-level Celera manager to leave at the end of the year — Terrence Ryan, former director of cell biology, left to join GlaxoSmithKline as director of integrative biology — Patterson says one of the primary drivers for the move was a desire to return to the California Southland. “It’s an opportunity to come back to southern California,” he says. “It’s where the family likes.”
As for why he left Celera, Patterson says he felt he had completed the task set out for him: to build a large-scale differential proteomics operation. “The group’s built and it’s operating, which is very pleasing to see,” he says. Last summer, Patterson’s group completed a differential protein expression study on pancreatic “normal-like” and cancer cell lines, and began a similar study of lung cancer tissue.
His experience at Celera will be critical for Farmal, where Patterson says he’ll set up the same type of proteomics facility, though not on the same scale.
The departure of Patterson and Ryan comes after a period of internal review precipitated by the arrival of Kathy Ordoñez as Celera’s president last spring and the company’s shifted emphasis on developing candidate drugs and diagnostics. “Everything is up for review,” Patterson told GT sister publication Proteo-Monitor last May. “Are we planning a big reduction in scale? No,” he said at the time. “We have a few planned projects, but I don’t have a crystal ball.”
— John S. MacNeil